Use of methylene amide derivatives in cardiovascular disorders

A method of using a methylene amide derivative of Formula (I)

• as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein
• R1 is selected from the group consisting essentially of (C1-C15)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl or heterocycloalkyl, (C1-C12)alkyl-aryl or (C1-C12)alkyl-heteroaryl, (C2-C12)alkenyl-aryl or -heteroaryl, (C2-C12)alkynyl-aryl and -heteroaryl;
• R2a and R2b are each independently from each other selected from the group consisting essentially of H and (C1-C12)alkyl;
• Cy is selected from D and E;
• D is selected from the group consisting essentially of substituted thienyl and substituted phenyl wherein substituents are selected from the group consisting essentially of phenyl, oxadiazole and 1 or 2 moieties selected from the group consisting essentially of —NH—CO—R3, —SO2—NR3R3′, and —CO—NR3R3′;
• E is selected from the group consisting essentially of aryl, heteroaryl, (3-8-membered)-cycloalkyl and heterocycloalkyl wherein aryl, heteroaryl, (3-8-membered)-cycloalkyl and heterocycloalkyl are substituted by (C2-C18)alkynyl;
• R3, R3′ are independently selected from the group consisting essentially of H, (C1-C15)alkyl, (C2-C12)alkenyl, (C2-C12)alkynyl, aryl, -heteroaryl, (3-8-membered)cycloalkyl or heterocycloalkyl, (C1-C12)alkyl aryl or heteroaryl, (C2-C12)alkenyl-aryl or heteroaryl, (C2-C12)alkynyl-aryl or -heteroaryl;
• for the treatment and/or prevention of cardiovascular disorders.